MBX Biosciences

MBX Biosciences At MBX Biosciences, our mission is to help transform the lives of people living with obesity and rare endocrine disorders.

Using our peptide delivery platform, we are advancing a pipeline of novel Precision Endocrine Peptides (PEPs)™ designed to overcome key limitations of existing treatments and improve efficacy, tolerability, safety, and convenience. Our lead candidate, canvuparatide (MBX 2109) – a potential once-weekly parathyroid hormone (PTH) replacement therapy for the treatment of chronic hypoparathyroidism – i

s preparing for Phase 3 development. We are also advancing an obesity portfolio including MBX 4291, a GLP-1/GIP co-agonist prodrug in Phase 1 development, and MBX 5765, an amycretin prodrug in preclinical development. In addition, we are on track to nominate its GLP-1/GIP/GCG receptor prodrug candidate in Q3 2026, further expanding its obesity pipeline to potentially address the full spectrum of patient needs. Learn more about our pipeline and peptide delivery platform: www.mbxbio.com.

08/27/2026

Today we are excited to announce that the first patient has been dosed in the pivotal Phase 3 oPTimize trial evaluating its once-weekly, investigational parathyroid hormone (PTH) replacement therapy for the treatment of adults with chronic hypoparathyroidism (HP).

The global registrational study will enroll approximately 160 patients and builds on positive Phase 2 Avail™ results and durable one-year data demonstrating sustained clinical benefit.

We look forward to advancing the oPTimize trial as we work to bring this potential therapy one step closer to people living with HP.

Read more about the Phase 3 oPTimize trial: https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-announces-first-patient-dosed-pivotal-phase-3

By 2035, 25% of the global population is projected to have obesity. Meanwhile, many patients discontinue current treatme...
07/13/2026

By 2035, 25% of the global population is projected to have obesity.

Meanwhile, many patients discontinue current treatments within 1–2 years – often driven by GI-related tolerability issues– highlighting the need for additional options.

Katherine Saunders, MD, FTOS, Co-Founder at FlyteHealth and Clinical Assistant Professor at Weill Cornell Medicine, shared these insights at our recent Obesity Day for investors.

At MBX Biosciences, we’re working to advance precision peptide therapies to help address these challenges for people living with obesity.

Learn more: https://investors.mbxbio.com/news-events/events

As the biotech industry marks 50 years of progress, MBX is proud to support the Biotechnology Innovation Organization - ...
06/22/2026

As the biotech industry marks 50 years of progress, MBX is proud to support the Biotechnology Innovation Organization - BIO’s campaign – spotlighting the breakthroughs, patients, and scientists driving innovation forward.

We are proud to be part of an industry that has transformed lives over the past five decades and look forward to contributing to continued progress as we advance scientific innovation for people living with rare endocrine and metabolic diseases through our Precision Endocrine Peptide (PEP)™ platform.

Explore the impact of biotech over the past 50 years: fightofourlives.com/timeline

June 1 marks – an opportunity to spotlight hypoparathyroidism (HP) and the more than 100,000 people in the U.S. living...
06/01/2026

June 1 marks – an opportunity to spotlight hypoparathyroidism (HP) and the more than 100,000 people in the U.S. living with this rare endocrine disorder.

At MBX, we’re proud to partner with the HypoPARAthyroidism Association, Inc.], whose dedicated efforts support patients and families through education, community, research, and advocacy.

While awareness days play an important role, the need for progress in HP extends well beyond a single moment. We remain committed to advancing the science and leveraging our Precision Endocrine Peptide (PEP™) platform to help address the ongoing unmet needs of people living with HP.

On , we celebrate the people behind scientific progress. We are grateful to our team of talented researchers at MBX, an...
05/20/2026

On , we celebrate the people behind scientific progress.

We are grateful to our team of talented researchers at MBX, and to the patients who inspire our work and drive clinical research forward every day.

Without their dedication, resilience, and trust, we would not be able to advance our mission of delivering innovative science to address unmet needs in endocrine and metabolic disorders.

Learn more about MBX’s clinical programs, including our planned Phase 3 trial investigating a once-weekly parathyroid hormone prodrug for chronic hypoparathyroidism: https://mbxbio.com/our-pipeline

This , we join the European Society of Endocrinology (ESE) to raise awareness of the far‑reaching impact of hormone imb...
04/24/2026

This , we join the European Society of Endocrinology (ESE) to raise awareness of the far‑reaching impact of hormone imbalances, which can drive chronic conditions like obesity and more than 400 rare endocrine diseases, including hypoparathyroidism.

At MBX, we are leveraging our Precision Endocrine Peptides™ (PEP™) Platform Technology to develop targeted therapies for rare endocrine disorders. Our PEPs are designed to address unmet needs and give hope to patients.

Learn more: mbxbio.com.

04/07/2026

This , MBX is proud to support the World Health Organization (WHO)'s call to .

We believe science has the power to help people living with endocrine and metabolic disorders live fuller, healthier lives. Guided by our commitment to innovation, our team of researchers is advancing new approaches aimed at making a meaningful difference in the treatment landscape for hypoparathyroidism, obesity, and post‑bariatric hypoglycemia.

Learn more about our commitment to science‑led innovation: mbxbio.com

Address

Carmel, IN

Website

Alerts

Be the first to know and let us send you an email when MBX Biosciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to MBX Biosciences:

Shortcuts

Share

Category